03 Jul 2026 ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI Icon check
08 Jun 2026 ADOCIA Announces THDB0206 (BioChaperone® Lispro) Phase 3 Data in Type 2 Diabetes Presented at ADA 86th Scientific Sessions, Confirming the Positive Results Previously Announced in July 2025 Icon check
04 Jun 2026 Adocia Announces a Virtual KOL Event to Review the Phase 3 Results of the Ultra-Rapid Insulin BioChaperone® Lispro on June 16, 2026 Icon check
12 May 2026 ADOCIA Reports First Quarter 2026 Financial Results and Provides a Business Update Icon check
11 May 2026 ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 3rd, 2026 in Paris Icon check
29 Apr 2026 ADOCIA Announces the Release of its Universal Registration Document for the Year 2025 Icon check
21 Apr 2026 ADOCIA Announces Full Year 2025 Financial Results and Provides a Corporate and Financial Update Icon check
21 Apr 2026 ADOCIA and Vester Finance sign a shareholder loan agreement, enabling ADOCIA to extend its cash runway until beginning Q2 2027 Icon check
24 Feb 2026 ADOCIA Reports Fourth Quarter 2025 Financial Results and Provides a Business Update Icon check
18 Dec 2025 ADOCIA Announces its Financial Calendar for 2026 Icon check
04 Dec 2025 ADOCIA Announces the Completion of a €10 Million Fundraising Icon check
12 Nov 2025 ADOCIA Announces Filing of Patent for New Long-Acting Peptides Platform in Diabetes and Obesity – AdoXLong – and Provides an Update on its BioChaperone® Platform Icon check
15 Oct 2025 ADOCIA Reports Third Quarter 2025 Financial Results and Provides a Business Update Icon check
15 Oct 2025 ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in people with T1D Icon check
25 Sep 2025 ADOCIA Announces First Half 2025 Financial Results and Provides a Business Update Icon check
03 Sep 2025 ADOCIA Announces Oral Presentations on AdoShell® and BioChaperone® at EASD, ESB and PODD 2025 Annual Meetings Icon check
25 Jul 2025 ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in people with T2D Icon check
23 Jul 2025 ADOCIA Reports Second Quarter 2025 Financial Results and Provides a Business Update Icon check
24 Jun 2025 ADOCIA Presentations at ADA & IPITA Scientific Conferences Highlight Scalability and Good Translation of AdoShell® from Human Islets to Stem Cell-Derived Islets Icon check
21 May 2025 ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 11th, 2025 in Paris Icon check
14 May 2025 ADOCIA Reports First Quarter 2025 Financial Results and Provides a Business Update Icon check
30 Apr 2025 ADOCIA Announces the Release of its Universal Registration Document for the Year 2024 Icon check
28 Apr 2025 ADOCIA to Present New Data on AdoShell® at Upcoming Scientific Conferences – Showcasing Potential Curative Treatment for Type 1 Diabetes Icon check
17 Apr 2025 ADOCIA Announces Full Year 2024 Financial Results and Provides a Corporate and Financial Update Icon check
28 Feb 2025 ADOCIA Announces the Settlement-Delivery of its €9.7 Million Private Placement Icon check
26 Feb 2025 ADOCIA Announces the Successful Completion of a €9.7 Million Private Placement, Extending its Cash Runway to Q2 2026 Icon check
25 Feb 2025 ADOCIA Reports Fourth Quarter 2024 Financial Results and Provides a Business Update Icon check
23 Dec 2024 ADOCIA Announces Its Participation at Upcoming Investor Conferences in 2025 Icon check
12 Dec 2024 ADOCIA and Tonghua Dongbao Announce the Final Dosing in a Phase 3 Clinical Study of BioChaperone® Lispro, Milestone Associated with a $10 Million Payment Icon check
30 Oct 2024 ADOCIA Reports Third Quarter 2024 Financial Results and Provides a Business Update Icon check
15 Oct 2024 ADOCIA announces patenting stable combinations of GLP-1 and amylin analogs for the treatment of obesity and diabetes using its BioChaperone® platform Icon check
23 Sep 2024 ADOCIA Announces Appointment of Mathieu William Gilbert as Chief Financial Officer Icon check
19 Sep 2024 ADOCIA Announces First Half 2024 Financial Results and Provides a Business Update Icon check
29 Aug 2024 ADOCIA to Deliver Oral Presentations on AdoShell® and AdoGel® at EASD Annual Meeting Icon check
24 Jul 2024 ADOCIA Reports Second Quarter 2024 Financial Results and Provides a Business Update Icon check
10 Jul 2024 ADOCIA Announces that Tonghua Dongbao is Discontinuing one of the two Partnership Programs: BioChaperone® Combo Icon check
18 Jun 2024 ADOCIA Announces Three Presentations at the American Diabetes Association 84th Scientific Sessions Icon check
03 Jun 2024 ADOCIA Announces Appointment of Mathieu William Gilbert as Chief Operating Officer Icon check
23 May 2024 ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 13th, 2024 in Paris Icon check
14 May 2024 ADOCIA Reports First Quarter 2024 Financial Results and Provides a Business Update Icon check
29 Apr 2024 ADOCIA Announces the Release of its Universal Registration Document for the Year 2023 Icon check
24 Apr 2024 ADOCIA Announces Full Year 2023 Financial Results and Provides a Corporate and Financial Update Icon check
21 Mar 2024 ADOCIA Announces a €2 Million Fundraising from its two Main Shareholders and a Member of its Management, and the Signature of an Equity Financing Line with Vester Finance Icon check
06 Mar 2024 ADOCIA Announces Its Participation at Key Events Icon check
27 Feb 2024 ADOCIA Reports Fourth Quarter 2023 Financial Results and Provides a Business Update Icon check
25 Jan 2024 ADOCIA Announces its Financial Calendar for 2024 Icon check
23 Nov 2023 Letter to Shareholders – November 2023 Icon check
09 Nov 2023 ADOCIA Revealed Promising Preclinical Data on AdoShell® Islets for Cell Therapy of Diabetes Icon check
25 Oct 2023 ADOCIA Reports Financial Results of Third Quarter 2023 and Provides an Update on its Activities Icon check
23 Oct 2023 ADOCIA’s Partner Tonghua Dongbao Announces Positive Results of Three Clinical Trials on BioChaperone® Combo Icon check
Join our mailing list. Subscribe